Weight-Loss drug may curb alcohol cravings in fatty liver patients
NCT ID NCT06546384
First seen Mar 12, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This study tests whether semaglutide (a GLP-1 drug used for diabetes and weight loss) can help people with obesity and fatty liver disease reduce or stop drinking alcohol. 64 participants will receive either semaglutide injections plus lifestyle counseling, or counseling alone. The main goal is to see if more people in the drug group achieve total alcohol abstinence after 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Bern
Bern, 3010, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide
What this could lead to
If it works, this could point toward a new way to help people with obesity and fatty liver cut down on alcohol.
What could go wrong
This is a small, early-stage trial with only 64 people. It may not show a clear benefit, and semaglutide can cause nausea and other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.